MicroRNAs in IgA nephropathy

Nature Reviews Nephrology

Volumn 10, Issue 5, 2014, Pages 249-256

  Szeto, Cheuk Chun ^a   Li, Philip K T ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TROPOMYOSIN; COLLAGEN TYPE 1; COLLAGEN TYPE 2; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A1; MESSENGER RNA; MICRORNA; MICRORNA 146A; MICRORNA 148B; MICRORNA 155; MICRORNA 192; MICRORNA 200; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MICRORNA 205; MICRORNA 29; MICRORNA 29B; SCLEROPROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UVOMORULIN;

3' UNTRANSLATED REGION; ANTIGEN ANTIBODY COMPLEX; CELL METABOLISM; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DISEASE CONTROL; DISEASE COURSE; DISEASE SEVERITY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENETIC ASSOCIATION; GLOMERULONEPHRITIS; GLOMERULOSCLEROSIS; GLYCOSYLATION; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY TUBULE CELL; NONHUMAN; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SEQUENCE ALIGNMENT; URINE LEVEL; URINE SEDIMENT;

BIOLOGICAL MARKERS; DISEASE PROGRESSION; GLOMERULONEPHRITIS, IGA; GLYCOSYLATION; HUMANS; KIDNEY; MICRORNAS;

EID: 85047687934     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2014.50     Document Type: Review

References (75)

1. Wyatt, R. J. & Julian, B. A. IgA nephropathy. N. Engl. J. Med. 368, 2402-2414 (2013).
2. Li, P. K., Ho, K. K., Szeto, C. C., Yu, L. & Lai, F. M. Prognostic indicators of IgA nephropathy in the Chinese-clinical and pathological perspectives. Nephrol. Dial. Transplant. 17, 64-69 (2002).
3. Le, W. et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol. Dial. Transplant. 27, 1479-1485 (2012).
4. Zuo, L. & Wang, M. Current burden and probable increasing incidence of ESRD in China. Clin. Nephrol. 74 (Suppl. 1), S20-S22 (2010).
5. rd edn (eds Davison, A. M. et al.) 469-501 (Oxford University Press, 2005).
6. Ho, Y.-W. et al. Hong Kong Renal Registry Report 2010. Hong Kong J. Nephrol. 12, 81-98 (2010).
7. Knoop, T. et al. Mortality in patients with IgA nephropathy. Am. J. Kidney Dis. 62, 883-890 (2013).
8. Novak, J., Renfrow, M. B., Gharavi, A. G. & Julian, B. A. Pathogenesis of immunoglobulin A nephropathy. Curr. Opin. Nephrol. Hypertens. 22, 287-294 (2013).
9. Roos, A. & van Kooten, C. Underglycosylation of IgA in IgA nephropathy: more than a diagnostic marker? Kidney Int. 71, 1089-1091 (2007).
10. Boyd, J. K., Cheung, C. K., Molyneux, K., Feehally, J. & Barratt, J. An update on the pathogenesis and treatment of IgA nephropathy. Kidney Int. 81, 833-843 (2012).
11. 1 levels. Kidney Int. 71, 1148-1154 (2007).
12. 1 antibodies against mucosal and systemic antigens in IgA nephropathy. J. Am. Soc. Nephrol. 17, 3520-3528 (2006).
13. Li, G. S., Zhang, H., Lv, J. C., Shen, Y. & Wang, H. Y. Variants of C1GALT1 gene are associated with the genetic susceptibility to IgA nephropathy. Kidney Int. 71, 448-453 (2007).
14. 1 in IgA nephropathy. J. Am. Soc. Nephrol. 23, 814-824 (2012).
15. Meister, G. & Tuschl, T. Mechanisms of gene silencing by double-stranded RNA. Nature 431, 343-349 (2004).
16. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism and function. Cell 116, 281-297 (2004).
17. Morita, K. & Han, M. Multiple mechanisms are involved in regulating the expression of the developmental timing regulator lin-28 in Caenorhabditis elegans. EMBO J. 25, 5794-5804 (2006).
18. Chan, S. P., Ramaswamy, G., Choi, E. Y. & Slack, F. J. Identification of specific let-7 microRNA binding complexes in Caenorhabditis elegans. RNA 14, 2104-2114 (2008).
19. Bernstein, E. et al. Dicer is essential for mouse development. Nat. Genet. 35, 215-217 (2003).
20. Bartels, C. L. & Tsongalis, G. J. MicroRNAs, novel biomarkers for human cancer. Clin. Chem. 55, 623-631 (2009).
21. Xiao, C. & Rajewsky, K. MicroRNA control in the immune system, basic principles. Cell 136, 26-36 (2009).
22. Tian, Z., Greene, A. S., Pietrusz, J. L., Matus, I. R. & Liang, M. MicroRNA-target pairs in the rat kidney identified by microRNA microarray, proteomic, and bioinformatic analysis. Genome Res. 18, 404-411 (2008).
23. Sun, Y. et al. Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs. Nucleic Acids Res. 32, e188 (2004).
24. Gregory, P. A., Bracken, C. P., Bert, A. G. & Goodall, G. J. MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle 7, 3112-3118 (2008).
25. Neilson, E. G. Mechanisms of disease: fibroblasts-a new look at an old problem. Nat. Clin. Pract. Nephrol. 2, 101-108 (2006).
26. Burk, U. et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 9, 582-589 (2008).
27. Park, S.-M., Gaur, A. B., Lengyel, E. & Peter, M. E. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 22, 894-907 (2008).
28. Korpal, M., Lee, E. S., Hu, G. & Kang, Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J. Biol. Chem. 283, 14910-14914 (2008).
29. Bracken, C. P. et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res. 68, 7846-7854 (2008).
30. Gregory, P. A. et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 10, 593-601 (2008).
31. Lorenzen, J. M., Haller, H. & Thum, T. MicroRNAs as mediators and therapeutic targets in chronic kidney disease. Nat. Rev. Nephrol. 7, 286-294 (2011).
32. Chandrasekaran, K. et al. Role of microRNAs in kidney homeostasis and disease. Kidney Int. 81, 617-627 (2012).
33. Tan, K. et al. Genome-wide analysis of microRNAs expression profiling in patients with primary IgA nephropathy. Genome 56, 161-169 (2013).
34. Tanzer, A. & Stadler, P. F. Molecular evolution of a microRNA cluster. J. Mol. Biol. 339, 327-335 (2004).
35. Cloonan, N. et al. The miR-17-5p microRNA is a key regulator of the G1/S. phase cell cycle transition. Genome Biol. 9, R127 (2008).
36. Serva, A. et al. miR-17-5p regulates endocytic trafficking through targeting TBC1D2/Armus. PLoS ONE 7, e52555 (2012).
37. Dong, Y. et al. Tumor suppressor functions of miR-133a in colorectal cancer. Mol. Cancer Res. 11, 1051-1060 (2013).
38. Liu, W. et al. miR-133a regulates adipocyte browning in vivo. PLoS Genet. 9, e1003626 (2013).
39. Wang, J. et al. Repression of ATR pathway by miR-185 enhances radiation-induced apoptosis and proliferation inhibition. Cell Death Dis. 4, e699 (2013).
40. Silva, F. G., Chander, P., Pirani, C. L. & Hardy, M. A. Disappearance of glomerular mesangial IgA deposits after renal allograft transplantation. Transplantation 33, 241-246 (1982).
41. Chen, Y, Song, Y. X. & Wang, Z. N. The microRNA-148/152 family, multi-faceted players. Mol. Cancer 12, 43 (2013).
42. Liu, X. et al. MicroRNA-148/152 impair innate response and antigen presentation of TLR-triggered dendritic cells by targeting CaMKIIα. J. Immunol. 185, 7244-7251 (2010).
43. Cimino, D. et al. miR148b is a major coordinator of breast cancer progression in a relapse-associated microRNA signature by targeting ITGA5, ROCK1, PIK3CA, NRAS, and CSF1. FASEB J. 27, 1223-1235 (2013).
44. Roth, C. et al. Low levels of cell-free circulating miR-361-3p and miR-625* as blood-based markers for discriminating malignant from benign lung tumors. PLoS ONE 7, e38248 (2012).
45. Cao, J. et al. DNA methylation-mediated repression of miR-886-3p predicts poor outcome of human small cell lung cancer. Cancer Res. 73, 3326-3335 (2013).
46. Floege, J. The pathogenesis of IgA nephropathy, what is new and how does it change therapeutic approaches? Am. J. Kidney Dis. 58, 992-1004 (2011).
47. Loeffler, I. & Wolf, G. Transforming growth factor-β and the progression of renal disease. Nephrol. Dial. Transplant. 29 (Suppl. 1), i37-i45 (2014).
48. Liu, Y. et al. Renal medullary microRNAs in Dahl salt-sensitive rats, miR-29b regulates several collagens and related genes. Hypertension 55, 974-982 (2010).
49. Qin, W. et al. TGF-β/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J. Am. Soc. Nephrol. 22, 1462-1474 (2011).
50. Fang, Y. et al. miR-29c is downregulated in renal interstitial fibrosis in humans and rats and restored by HIF-α activation. Am. J. Physiol. Renal Physiol. 304, F1274-F1282 (2013).
51. Wang, G. et al. Intra-renal expression of microRNAs in patients with IgA nephropathy. Lab. Invest. 90, 98-103 (2010).
52. Wang, G. et al. Elevated levels of miR-146a and miR-155 in kidney biopsy and urine from patients with IgA nephropathy. Dis. Markers 30, 171-179 (2011).
53. Puhr, M. et al. Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am. J. Pathol. 181, 2188-2201 (2012).
54. Muratsu-Ikeda, S. et al. Downregulation of miR-205 modulates cell susceptibility to oxidative and endoplasmic reticulum stresses in renal tubular cells. PLoS ONE 7, e41462 (2012).
55. Yang, L. et al. miR-146a controls the resolution of T cell responses in mice. J. Exp. Med. 209, 1655-1670 (2012).
56. Ichii, O. et al. Altered expression of microRNA miR-146a correlates with the development of chronic renal inflammation. Kidney Int. 81, 280-292 (2012).
57. Vigorito, E., Kohlhaas, S., Lu, D. & Leyland, R. miR-155, an ancient regulator of the immune system. Immunol. Rev. 253, 146-157 (2013).
58. Chau, B. N. et al. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci. Transl. Med. 4, 121ra128 (2012).
59. Chung, A. C., Huang, X. R., Meng, X. & Lan, H. Y. miR-192 mediates TGF-β/Smad3-driven renal fibrosis. J. Am. Soc. Nephrol. 21, 1317-1325 (2010).
60. Krupa, A., Jenkins, R., Luo, D. D., Lewis, A., Phillips, A. & Fraser, D. Loss of microRNA-192 promotes fibrogenesis in diabetic nephropathy. J. Am. Soc. Nephrol. 21, 438-447 (2010).
61. Du, B. et al. High glucose down-regulates miR-29a to increase collagen IV production in HK-2 cells. FEBS Lett. 584, 811-816 (2010).
62. Wang, Q. et al. MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. FASEB J. 22, 4126-4135 (2008).
63. Fleissner, F. et al. Short communication, asymmetric dimethylarginine impairs angiogenic progenitor cell function in patients with coronary artery disease through a microRNA-21-dependent mechanism. Circ. Res. 107, 138-143 (2010).
64. Hanke, M. et al. A robust methodology to study urine microRNA as tumor marker, microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol. Oncol. 28, 655-661 (2010).
65. Cortez, M. A. & Calin, G. A. MicroRNA identification in plasma and serum, a new tool to diagnose and monitor diseases. Expert Opin. Biol. Ther. 9, 703-711 (2009).
66. Mitchell, P. S. et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA 105, 10513-10518 (2008).
67. Gilad, S. et al. Serum microRNAs are promising novel biomarkers. PLoS ONE 3, e3148 (2008).
68. Lorenzen, J. M. et al. Urinary miR-210 as a mediator of acute T-cell mediated rejection in renal allograft recipients. Am. J. Transplant. 11, 2221-2227 (2011).
69. Wang, G. et al. Serum and urinary free microRNA level in patients with systemic lupus erythematosus. Lupus 20, 493-500 (2011).
70. Wang, G. & Szeto, C. C. Methods of microRNA quantification in urinary sediment. Methods Mol. Biol. 1024, 211-220 (2013).
71. Turchinovich, A., Weiz, L., Langheinz, A. & Burwinkel, B. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 39, 7223-7233 (2011).
72. Wang, G. et al. Serum and urinary cell free miR-146a and miR-155 in patients with systemic lupus erythematosus. J. Rheumatol. 37, 2516-2522 (2010).
73. Wang, G. et al. Urinary miR-21, miR-29, and miR-93, novel biomarkers of fibrosis. Am. J. Nephrol. 36, 412-418 (2012).
74. Szeto, C. C. et al. Micro-RNA expression in the urinary sediment of patients with chronic kidney diseases. Dis. Markers 33, 137-144 (2012).
75. Wang, G. et al. Expression of microRNAs in the urinary sediment of patients with IgA nephropathy. Dis. Markers 28, 79-86 (2010).